Related Experiment Videos
[Topoisomerases: therapeutic value]
1Pharmacie, Hôpital Saint-Louis, Paris.
Abstract:
Anticancer pharmacology offers rich prospects for future therapeutic design. Knowledge of antitumoral agents pharmacology have widely advanced: understanding of the molecular cytotoxic mechanism of available agents, discovery of new compounds with a different and no-interfering mechanism of action. Since ten years, the identification of a couple of nuclear enzyme, DNA-topoisomerases, has answered to this goal. These enzymes catalyse the topological changes of the double strand DNA, participating to vital processes of cell metabolism. These enzymes are now know to be the intracellular target of widely used cytotoxic agents (such as anthracycline, Etoposide, Teniposide for DNA topoisomerase II) and for two new compounds in clinical trials (irinotecan and topotecan, both analogues of camptothecin, for DNA-topoisomerase I). This two last molecules, currently in phase II development, are promising. They seem to be synergistic in combination with available anticancer agents, but this remains to be demonstrated. Other drugs, inhibiting both DNA-topoisomerases I and II, are yet investigating. Would they provide new answers for the future?
Insights
Anticancer drug development is advancing by targeting DNA topoisomerases, crucial nuclear enzymes involved in DNA replication and repair. New drugs targeting these enzymes show promise for improved cancer therapies.
Area of Science:
- Pharmacology
- Molecular Biology
- Oncology
Context:
- Anticancer drug discovery is rapidly evolving.
- Understanding molecular cytotoxic mechanisms is key.
- Novel compounds with distinct mechanisms of action are sought.
Purpose:
- To explore the role of DNA topoisomerases as targets for anticancer agents.
- To review current and emerging drugs targeting DNA topoisomerase I and II.
- To assess the therapeutic potential of these agents in cancer treatment.
Summary:
- DNA topoisomerases (I and II) are nuclear enzymes critical for DNA topology.
- These enzymes are the targets of established cytotoxic agents (e.g., anthracyclines, etoposide) and novel compounds (e.g., irinotecan, topotecan).
- Emerging drugs targeting both topoisomerase I and II are under investigation for enhanced efficacy.
Impact:
- Advances in anticancer pharmacology offer new therapeutic design strategies.
- Targeting DNA topoisomerases represents a significant area for developing novel cancer treatments.
- Further research into dual topoisomerase inhibitors may yield synergistic effects and improved patient outcomes.